Rebekah P. Dyer

Rebekah P. Dyer

Auto-generated profile, based on publicly available information

Rebekah P. Dyer

Department of Molecular Biology and Biochemistry, University of California, Irvine, 1102 NS-2, Irvine, CA 92697-2025 USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Cell Chemical Biology
Verified
Journal Article
Open access
RDRebekah P. Dyer
Rebekah P. Dyer
GWGregory A. Weiss
Gregory A. Weiss
Proteases cut with enviable precision and regulate diverse molecular events in biology. Such qualities drive a seemingly inexhaustible appetite for proteases with new activities and capabilities. Comprising 25% of the total industrial enzyme market, proteases appear in consumer goods, such as detergents, textile processing, and numerous foods; additionally, proteases include 25 FDA-approved medicines and various research tools. Recent advances in protease engineering strategies address target specificity, catalytic efficiency, and stability. This tunable guide for protease engineering surveys best practices and emerging strategies. We further highlight gaps and flexibilities inherent to each system that suggest opportunities for new technology development along with engineered proteases to solve challenges in proteomics, protein sequencing, and synthetic gene circuits.

30 January 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JBJoshua Britton
Joshua Britton
RDRebekah P. Dyer
Rebekah P. Dyer
SMSudipta Majumdar
Sudipta Majumdar
Colin Llewellyn RastonColin Llewellyn Raston
Colin Llewellyn Raston
GWGregory A. Weiss
Gregory A. Weiss

22 January 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
AAAisha M. Attar
Aisha M. Attar
MRMark B. Richardson
Mark B. Richardson
GSGaetano Speciale
Gaetano Speciale
SMSudipta Majumdar
Sudipta Majumdar
RDRebekah P. Dyer
Rebekah P. Dyer
GWGregory A. Weiss
Gregory A. Weiss

28 April 2021 in mSphere
Verified
Journal Article
Open access
SSSanjana R. Sen
Sanjana R. Sen
Emily C. SandersEmily C. Sanders
Emily C. Sanders
KGKristin N. Gabriel
Kristin N. Gabriel
BMBrian M. Miller
Brian M. Miller
HIHariny M. Isoda
Hariny M. Isoda
GWGregory A. Weiss
Gregory A. Weiss
The COVID-19 pandemic has resulted in over two million deaths worldwide. Despite efforts to fight the virus, the disease continues to overwhelm hospitals with severely ill patients.

17 April 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
MRMark B. Richardson
Mark B. Richardson
KGKristin Nichelle Gabriel
Kristin Nichelle Gabriel
JGJoseph A. Garcia
Joseph A. Garcia
SAShareen N. Ashby
Shareen N. Ashby
RDRebekah P. Dyer
Rebekah P. Dyer
GWGregory A. Weiss
Gregory A. Weiss

16 October 2020 in bioRxiv
Verified
Preprint
Open access
SSS. Sen
S. Sen
E.C. SandersE.C. Sanders
E.C. Sanders
KGK.N. Gabriel
K.N. Gabriel
BMB.M. Miller
B.M. Miller
HIH.M. Isoda
H.M. Isoda
GWGregory A. Weiss
Gregory A. Weiss
Effective methods for predicting COVID-19 disease trajectories are urgently needed. Here, ELISA and coronavirus antigen microarray (COVAM) analysis mapped antibody epitopes in the plasma of COVID-19 patients (n = 86) experiencing a wide-range of disease states. The experiments identified antibodies to a 21-residue epitope from nucleocapsid (termed Ep9) associated with severe disease, including admission to the ICU, requirement for ventilators, or death. Importantly, anti-Ep9 antibodies can be detected within six days post-symptom onset and sometimes within one day. Furthermore, anti-Ep9 antibodies correlate with various comorbidities and hallmarks of immune hyperactivity. We introduce a simple-to-calculate, disease risk factor score to quantitate each patient’s comorbidities and age. For patients with anti-Ep9 antibodies, scores above 3.0 predict more severe disease outcomes with a 13.42 Likelihood Ratio (96.7% specificity). The results lay the groundwork for a new type of COVID-19 prognostic to allow early identification and triage of high-risk patients. Such information could guide more effective therapeutic intervention. Significance statement: The COVID-19 pandemic has resulted in over two million deaths worldwide. Despite efforts to fight the virus, the disease continues to overwhelm hospitals with severely ill patients. Diagnosis of COVID-19 is readily accomplished through a multitude of reliable testing platforms; however, prognostic prediction remains elusive. To this end, we identified a short epitope from the SARS-CoV-2 nucleocapsid protein and also a disease risk factor score based upon comorbidities and age. The presence of antibodies specifically binding to this epitope plus a score cutoff can predict severe COVID-19 outcomes with 96.7% specificity.